Mundipharma gains rights to develop and commercialize Grafalon in China and Japan

Neovii Pharmaceuticals AG (Rapperswil, Switzerland) granted Mundipharma International

Read the full 85 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE